Reference number : GC-2017-Q2-04378, amendment number : , agreement type : G, recipient legal name : Creuzenet, Carole (The University of Western Ontario), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for Universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : The bacterium Helicobacter pylori causes 65% of gastric ulcers and cancers worldwide. Antibiotic treatments_x000D_
have serious side effects and often fail because of bacterial resistance. Globally 30% of Canadians are_x000D_
colonized and the aging of the population allows more gastric cancers to develop over decades. About 95% of_x000D_
Aboriginals are colonized and suffer from high rates of gastric ulcers and treatment failure. Lactobacilli are_x000D_
bacteria naturally present in the gut that are known as good bacteria with probiotic activity. Lactobacilli_x000D_
formulations developed by industry partner Lallemand Health Solutions improve anti- H. pylori treatments in_x000D_
vivo and most of the 20 Lactobacilli tested in vitro in the Creuzenet lab released molecules with anti-H. pylori_x000D_
effects. However, the mechanisms underlying those effects are not understood._x000D_
We propose to examine how these molecules work, testing the hypothesis that they target specific sensors_x000D_
present in H. pylori. Understanding their mechanism of action will fill an important knowledge gap and will_x000D_
also provide validation of active strains by bona fide scientific evidence, which is often lacking in the probiotic_x000D_
field. This will benefit our industrial partner who has a well-established tradition of backing all efficacy claims_x000D_
by strong scientific data._x000D_
Also, our work will help identify the best Lactobacilli to be used for specific purposes and facilitate the_x000D_
identification of the beneficial anti-H. pylori molecules, which could be used in purified form to potentiate live_x000D_
probiotics in mixed formulations or to enhance the efficacy of current antibiotic treatments. These are direct_x000D_
benefits to the H. pylori-infected patients and the industrial partner who can explore a potentially significant_x000D_
market._x000D_
Furthermore, understanding the molecular interactions that occur between H. pylori and Lactobacilli could_x000D_
serve as a model system for other complex bacterial interactions. This could yield applications extending to_x000D_
other fields, such as nutrition, biotechnology or even bioremediation., program purpose french : The bacterium Helicobacter pylori causes 65% of gastric ulcers and cancers worldwide. Antibiotic treatments_x000D_
have serious side effects and often fail because of bacterial resistance. Globally 30% of Canadians are_x000D_
colonized and the aging of the population allows more gastric cancers to develop over decades. About 95% of_x000D_
Aboriginals are colonized and suffer from high rates of gastric ulcers and treatment failure. Lactobacilli are_x000D_
bacteria naturally present in the gut that are known as good bacteria with probiotic activity. Lactobacilli_x000D_
formulations developed by industry partner Lallemand Health Solutions improve anti- H. pylori treatments in_x000D_
vivo and most of the 20 Lactobacilli tested in vitro in the Creuzenet lab released molecules with anti-H. pylori_x000D_
effects. However, the mechanisms underlying those effects are not understood._x000D_
We propose to examine how these molecules work, testing the hypothesis that they target specific sensors_x000D_
present in H. pylori. Understanding their mechanism of action will fill an important knowledge gap and will_x000D_
also provide validation of active strains by bona fide scientific evidence, which is often lacking in the probiotic_x000D_
field. This will benefit our industrial partner who has a well-established tradition of backing all efficacy claims_x000D_
by strong scientific data._x000D_
Also, our work will help identify the best Lactobacilli to be used for specific purposes and facilitate the_x000D_
identification of the beneficial anti-H. pylori molecules, which could be used in purified form to potentiate live_x000D_
probiotics in mixed formulations or to enhance the efficacy of current antibiotic treatments. These are direct_x000D_
benefits to the H. pylori-infected patients and the industrial partner who can explore a potentially significant_x000D_
market._x000D_
Furthermore, understanding the molecular interactions that occur between H. pylori and Lactobacilli could_x000D_
serve as a model system for other complex bacterial interactions. This could yield applications extending to_x000D_
other fields, such as nutrition, biotechnology or even bioremediation., agreement title english : Mechanisms underlying the anti-Helicobacter pylori effects of Lactobacilli secretomes, agreement title french : Mechanisms underlying the anti-Helicobacter pylori effects of Lactobacilli secretomes, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-09-20, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada